AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20415914
Drug: Gumtone gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gumtone gel
Trial: 16040409
Drug: Tazarotene 0.1%
RxNorm normalized name: TAZAROTENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazarotene 0.1% gel plus petrolatum once daily
Trial: 16040409
Drug: Calcipotriol 0.005%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol 0.005% ointment twice daily
Trial: 11791028
Drug: Irbesartan (AT1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (AT1 antagonist)
Trial: 10530535
Drug: Intravenous analgesia/sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous analgesia/sedation (IVAS)
Trial: 10530535
Drug: Intraarticular lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarticular lidocaine injection (IAL)
Trial: 30485450
Drug: Placebo formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo formulation
Trial: 15155349
Drug: 40 mL
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL chloroprocaine 1%
Trial: 15155349
Drug: 40 mL
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL chloroprocaine 0.5%
Trial: 8082071
Drug: Chemoembolization (5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoembolization (5-fluorouracil 750 mg/m2 and recombinant alpha-2a-interferon 9-MU mixed into PVA contrast suspension)
Trial: 2919760
Drug: Midazolam (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.3 mg/kg intravenously)
Trial: 4025853
Drug: Thiopental (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental (4 mg/kg)
Trial: 31739784
Drug: Internal Brace
RxNorm normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Internal Brace Ligament Augmentation (IBLA)
Trial: 28072690
Drug: Insulin jet
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin jet injector (regular insulin and insulin aspart)
Trial: 28072690
Drug: Insulin pen
RxNorm normalized name: INSULIN PEN (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin pen (regular insulin and insulin aspart)
Trial: 25879228
Drug: Red yeast
RxNorm normalized name: red yeast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red yeast rice and olive fruit extract (10.82 mg of monacolins and 9.32 mg of hydroxytyrosol per capsule)
Trial: 20238221
Drug: Combined connective
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined connective tissue massage, Kabat's technique, kinesitherapy, and home exercise program for 9 weeks (twice a week, 1 hour per session)
Trial: 19884713
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of in-office (CP37) and at-home (CP10) bleaching
Trial: 17261397
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no statin treatment)
Trial: 9695725
Drug: Entacapone (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entacapone (50, 100, 200, or 400 mg)
Trial: 28155060
Drug: Antibiotic-loaded DAC®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic-loaded DAC® hydrogel coating
Trial: 25162362
Drug: PEG 4000
RxNorm normalized name: PEG 4000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG 4000 at a dose of 0.7 g/kg (high-dose group)
Trial: 25162362
Drug: PEG 4000
RxNorm normalized name: PEG 4000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG 4000 at a dose of 0.3 g/kg (low-dose group)
Trial: 12684359
Drug: Behavior Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior Therapy (BT) and Sibutramine
Trial: 12684359
Drug: Behavior Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior Therapy (BT) and Placebo
Trial: 12684359
Drug: Sibutramine (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine (after initial treatment)
Trial: 10194542
Drug: Irinotecan (CPT‐11)
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan (CPT‐11) administered via 90 min i.v. infusion
Trial: 376459
Drug: NAB 365
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NAB 365 (clenbuterol) administered at 30 micrograms b.i.d. for 3 days, then reduced to 20 micrograms b.i.d. for an average of 13 days.
Trial: 376459
Drug: Salbutamol administered
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol administered at 4 mg t.i.d. for an average of 13 days.
Trial: 25179260
Drug: VCD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VCD treatment
Trial: 23345050
Drug: Piperacillin/tazobactam (PIPC/TAZ,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam (PIPC/TAZ, 13.5 g/day)
Trial: 23345050
Drug: Meropenem (MEPM,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (MEPM, 1.5 g/day)
Trial: 17932841
Drug: 1-day application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-day application of topical 0.5% levofloxacin
Trial: 17932841
Drug: 3-day application
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-day application of topical 0.5% levofloxacin
Trial: 11175234
Drug: Nocturnal transtracheal
RxNorm normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nocturnal transtracheal augmented ventilation (TTAV) at 10 L/min
Trial: 11367663
Drug: Qingyu Jiuxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingyu Jiuxin Pills (QYJXP)
Trial: 8154033
Drug: imipenem/cilastatin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: imipenem/cilastatin (500 mg)
Trial: 8154033
Drug: placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (100 ml)
Trial: 29316960
Drug: Pregabalin (PGB)
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin (PGB) 150-300 mg twice daily for 8 weeks
Trial: 29316960
Drug: Gabapentin (GBP)
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin (GBP) 400-800 mg three times daily for 8 weeks
Trial: 22883608
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose 5-ALA (15 mg capsule)
Trial: 22883608
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose 5-ALA (50 mg capsule)
Trial: 22883608
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo capsule)
Trial: 15459595
Drug: Amiodarone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (15 mg/kg IV over 24 hours followed by 200 mg orally 3 times per day for 7 days)
Trial: 15459595
Drug: Sotalol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol (80 mg orally 2 times per day for 7 days)
Trial: 11174041
Drug: High-dose folic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose folic acid, vitamin B6, and vitamin B12 supplements
Trial: 11174041
Drug: Lower doses
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower doses of folic acid, vitamin B6, and vitamin B12 supplements
Trial: 9253332
Drug: PTHrP (parathyroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTHrP (parathyroid hormone-related peptide-(1-34))
Trial: 8494580
Drug: Azelastine nasal
RxNorm normalized name: azelastine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine nasal spray (0.14 mg/nostril b.i.d.)
Trial: 8494580
Drug: Budesonide nasal
RxNorm normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide nasal aerosol (0.05 mg/nostril b.i.d.)
Trial: 8494580
Drug: Azelastine nasal
RxNorm normalized name: azelastine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine nasal spray and Budesonide nasal aerosol
Trial: 3320788
Drug: Carvedilol, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol, a new beta-adrenergic blocking agent with direct vasodilator activity, administered orally.
Trial: 27282118
Drug: Enhanced treatment-as-usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment-as-usual (ETAU)
Trial: 30085876
Drug: Enamel deproteinization,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enamel deproteinization, acid etching, bonding agent application, and pit & fissure sealant placement
Trial: 27714541
Drug: Cabozantinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib (100 mg daily during a 12-week lead-in stage)
Trial: 24990101
Drug: Full portion
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full portion aerated drink (1,000 ml, 190 kcal)
Trial: 24990101
Drug: Half portion
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half portion aerated drink (500 ml, 95 kcal)
Trial: 24990101
Drug: Full portion
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full portion liquid drink (325 ml, 190 kcal)
Trial: 24990101
Drug: Half portion
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half portion liquid drink (162 ml, 95 kcal)
Trial: 18201301
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (BoNT‐A) injections into the submandibular and parotid glands; 25 units of BoNT‐A into each gland.
Trial: 12082182
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received no treatment.
Trial: 19619146
Drug: DHEA 50
RxNorm normalized name: Natrol Mood & Stress DHEA 50mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 50 mg daily
Trial: 9288699
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen (CEE) 0.625 mg daily
Trial: 15989411
Drug: DHEA 50
RxNorm normalized name: Natrol Mood & Stress DHEA 50mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 50 mg + CEE 0.625 mg daily
Trial: 10494116
Drug: Intravesical instillation
RxNorm normalized name: ADSTILADRIN Suspension for Intravesical Instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation of 15 mg trospium chloride in 40 ml saline
Trial: 10494116
Drug: Intravesical instillation
RxNorm normalized name: ADSTILADRIN Suspension for Intravesical Instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation of 30 mg trospium chloride in 40 ml saline
Trial: 8702086
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (conjugated estrogens, 0.625 mg/d and medroxyprogesterone, 5 mg/d)
Trial: 6751514
Drug: Cytoreductive surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive surgery followed by cis-platinum containing combination chemotherapy
Trial: 29017511
Drug: Mechanical wrist
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical wrist traction (12 treatments, twice a week for 6 weeks)
Trial: 24368400
Drug: Everolimus 5
RxNorm normalized name: everolimus 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 5 mg/day plus erlotinib 150 mg/day
Trial: 20014909
Drug: Atomoxetine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (40 mg/day)
Trial: 14739125
Drug: Torcetrapib 10
RxNorm normalized name: Torcetrapib
DrugBank: Torcetrapib (DB06281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torcetrapib 10 mg daily
Trial: 14739125
Drug: Torcetrapib 30
RxNorm normalized name: Torcetrapib
DrugBank: Torcetrapib (DB06281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torcetrapib 30 mg daily
Trial: 14739125
Drug: Torcetrapib 60
RxNorm normalized name: Torcetrapib
DrugBank: Torcetrapib (DB06281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torcetrapib 60 mg daily
Trial: 14739125
Drug: Torcetrapib 120
RxNorm normalized name: Torcetrapib
DrugBank: Torcetrapib (DB06281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torcetrapib 120 mg daily
Trial: 14739125
Drug: Torcetrapib 120
RxNorm normalized name: Torcetrapib
DrugBank: Torcetrapib (DB06281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torcetrapib 120 mg twice daily
Trial: 3113329
Drug: Cefadroxil (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefadroxil (75 children), given once daily
Trial: 3113329
Drug: Phenoxymethyl penicillin
RxNorm normalized name: Phenoxymethyl Penicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenoxymethyl penicillin (75 children), given three times daily
Trial: 31975475
Drug: Topical selenium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical selenium (Se)
Trial: 28363480
Drug: 16 mg/day
RxNorm normalized name: futibatinib 16 mg/day (4 mg x 4) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg/day TRF-budesonide
Trial: 28363480
Drug: 8 mg/day
RxNorm normalized name: Neupro 8 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg/day TRF-budesonide
Trial: 24191330
Drug: Generic formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic formulation of flurbiprofen (tablet Flurso)
Trial: 24191330
Drug: Branded product
RxNorm normalized name: Eagle Brand Medicated Oil Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded product of flurbiprofen (tablet Ansaid)
Trial: 14747426
Drug: d‐MPH administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐MPH administered in a fasting state
Trial: 14747426
Drug: d‐MPH administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐MPH administered after a high‐fat breakfast
Trial: 14747426
Drug: d‐MPH administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐MPH administered with food
Trial: 12745746
Drug: 1.5% glycine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% glycine infusion at 0.5 ml/kg/min for 30 min
Trial: 12745746
Drug: 3% mannitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% mannitol infusion (control)
Trial: 12745746
Drug: 1.5% glycine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% glycine infusion
Trial: 8085509
Drug: Home Treatment
RxNorm normalized name: Home-brew
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home Treatment Team (HTT)
Trial: 29488152
Drug: Sitagliptin 50
RxNorm normalized name: SITagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 50 mg
Trial: 24516103
Drug: Sitagliptin 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 200 mg
Trial: 23881910
Drug: Maraviroc (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maraviroc (7 days administration)
Trial: 17909199
Drug: Bevacizumab +
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab + Chemotherapy
Trial: 9777793
Drug: Tazarotene-UVB treatment
RxNorm normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tazarotene-UVB treatment (tazarotene 0.1% gel once daily for 2 weeks followed by tazarotene plus UVB therapy 3 times per week for 10 weeks)
Trial: 4043476
Drug: UVB therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVB therapy alone
Trial: 9777793
Drug: UVB therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVB therapy plus vehicle gel
Trial: 7817163
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml (0.1 mg) fentanyl intravenously
Trial: 7817163
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml saline intravenously
Trial: 17649720
Drug: ATRA +
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ATRA + chemotherapy
Trial: 30056747
Drug: Melodic Intonation
RxNorm normalized name: ADAPTER,INTUBATION CAREFUSION #1820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melodic Intonation Therapy (12 sessions over six weeks)
Trial: 30056747
Drug: Waiting list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list control (no treatment initially)
Trial: 23940216
Drug: cediranib (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cediranib (30 mg) monotherapy
Trial: 23940216
Drug: cediranib (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cediranib (20 mg) plus lomustine (110 mg/m(2))
Trial: 23940216
Drug: lomustine (110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lomustine (110 mg/m(2)) plus placebo
Trial: 23940216
Drug: cediranib (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cediranib (30 mg) monotherapy and cediranib (20 mg) plus lomustine
Trial: 16627149
Drug: Mail administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mail administration of SF-36 and Oxford Hip questionnaires
Trial: 16627149
Drug: Interview administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interview administration of SF-36 and Oxford Hip questionnaires
Trial: 8605789
Drug: Flumazenil (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (maximum of 1 mg in double-blind phase, up to 2.5 mg in open phase)
Trial: 8605789
Drug: Flumazenil (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.7 +/- 0.3 mg)
Trial: 1874931
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg elemental calcium/day
Trial: 1874931
Drug: 2000 mg
RxNorm normalized name: bran 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg elemental calcium/day
Trial: 1874931
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (both doses)
Trial: 31371315
Drug: Low-dose dacarbazine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dacarbazine (DTIC) administered at 850 mg/m2 intravenously on days 1 and 28, and interferon‐alpha‐2b (IFN‐α‐2b) administered at 3 million units three times a week subcutaneously for 24 weeks beginning at week 9.
Trial: 31371315
Drug: Low-dose dacarbazine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dacarbazine (DTIC) and interferon‐alpha‐2b (IFN‐α‐2b)
Trial: 30149135
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri (2 × 10^8 CFU, twice daily during antibiotic treatment)
Trial: 26455249
Drug: Counselling group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counselling group (written instruction + monthly counselling)
Trial: 21545190
Drug: Ultrasound-guided injection
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided injection of methylprednisolone acetate 40 mg/mL with 0.8 mL lidocaine plus injection of 1 mL hyaluronic acid 0.8% 10 days later (n=15; group A)
Trial: 16634495
Drug: Early loading
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early loading of implants (< or = 14 days postimplantation)
Trial: 16634495
Drug: Standard loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard loading of implants (3 to 4 months postimplantation)
Trial: 8695094
Drug: Epidural PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural PCA (EPCA) with sufentanil: 0.3 microgram/kg bolus followed by 8 micrograms/hr infusion plus epidural PCA boluses of 4 micrograms every 6 min as needed
Trial: 8695094
Drug: i.v. PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. PCA with sufentanil: 0.3 microgram/kg bolus followed by 8 micrograms/hr infusion plus IV PCA boluses of 4 micrograms every 6 min as needed
Trial: 8695094
Drug: i.v. PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. PCA with morphine: 0.1 mg/kg bolus followed by 0.5 mg/hr infusion plus i.v. PCA boluses of 1 mg every 6 min as needed
Trial: 29432857
Drug: intensive antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intensive antiretroviral treatment strategy
Trial: 29432857
Drug: standard antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard antiretroviral treatment strategy
Trial: 29432857
Drug: interruption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: interruption of treatment
Trial: 29432857
Drug: continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: continuation of treatment